Abcuro
Updated: January 16, 2026
Founder Stefano Gullà
Country: USA | Funding: $414.8M (+)
Founded: 2015
Website: https://www.abcuro.com/
Abcuro develops immunotherapeutics for the treatment of autoimmune diseases and cancer. Its flagship antibody-drug Ulviprubart targets the selective elimination of highly cytotoxic T cells expressing KLRG1 while sparing key lymphocyte populations, including naive, memory, and regulatory T cells, which are essential for maintaining normal immune homeostasis. Ulviprubart is in clinical trials for the treatment of highly cytotoxic T cell-mediated diseases, including the autoimmune muscle disease inclusion body myositis, T-cell large granular lymphocytic leukemia and mature T-cell malignancies.
Founded: 2015
Website: https://www.abcuro.com/
Abcuro develops immunotherapeutics for the treatment of autoimmune diseases and cancer. Its flagship antibody-drug Ulviprubart targets the selective elimination of highly cytotoxic T cells expressing KLRG1 while sparing key lymphocyte populations, including naive, memory, and regulatory T cells, which are essential for maintaining normal immune homeostasis. Ulviprubart is in clinical trials for the treatment of highly cytotoxic T cell-mediated diseases, including the autoimmune muscle disease inclusion body myositis, T-cell large granular lymphocytic leukemia and mature T-cell malignancies.
